Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, M. N.
Right arrow Articles by Curiel, D. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, M. N.
Right arrow Articles by Curiel, D. T.

Clinical Cancer Research, Vol 2, Issue 7 1089-1095, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Novel gene therapy strategy to accomplish growth factor modulation induces enhanced tumor cell chemosensitivity

MN Barnes, JS Deshane, GP Siegal, RD Alvarez and DT Curiel
Departments of Obstetrics and Gynecology and Pathology, Cell Biology, and Surgery, and Gene Therapy Program, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA.

erbB-2 is a cell surface transmembrane glycoprotein which, when overexpressed, has been shown to be relevant to intrinsic tumor cell chemoresistance. Thus, strategies to down-regulate cell surface erbB-2 have resulted in enhanced tumor cell chemosensitivity. We have recently reported a gene therapy strategy to down-modulate erbB-2 expression using a plasmid construct encoding an intracellular single chain antibody. Therefore, we now demonstrate enhanced chemosensitivity to cis-diamminedichloroplatinum in erbB-2 overexpressing tumor cells and a model system of stable clones using an intracellular single chain antibody. These findings are consistent with the hypothesis that erbB-2 plays a role in tumor cell chemoresistance. In addition, these findings represent a novel gene therapy approach to overcome erbB-2-mediated tumor cell chemoresistance.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
K.-T. Chang, C.-Y. F. Huang, C.-M. Tsai, C.-H. Chiu, and Y.-Y. Lok
Role of IL-6 in neuroendocrine differentiation and chemosensitivity of non-small cell lung cancer
Am J Physiol Lung Cell Mol Physiol, September 1, 2005; 289(3): L438 - L445.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. M. Nguyen, A. Chen, A. Mixon, D. S. Schrump, and S. J. A. Roth
SEQUENCE-DEPENDENT ENHANCEMENT OF PACLITAXEL TOXICITY IN NON-SMALL CELL LUNG CANCER BY 17-ALLYLAMINO 17-DEMETHOXYGELDANAMYCIN
J. Thorac. Cardiovasc. Surg., November 1, 1999; 118(5): 908 - 915.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Smith, J. Abrams, E. L. Trimble, and R. S. Ungerleider
Dose Intensity of Chemotherapy for Childhood Cancers
Oncologist, October 1, 1996; 1(5): 293 - 304.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.